SAN DIEGO, Nov. 16, 2016 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Mallinckrodt Public Limited Company (NYSE: MNK) violated federal laws.
On November 16, 2016, Citron Research issued a report titled "Mallinckrodt CEO FRAUD exposed by the new Medicare Drug Dashboard". In this article, Citron stated that Mallinckrodt CEO has committed Fraud by lying to the shareholders about the Company's dependence on the Medicare system. Per Citron, Mallinckrodt drug Acthar, which is medically unproven, is now the most expensive drug reimbursed by Medicare. Citron has placed a price target of $20 on Mallinckrodt stock.
Johnson & Weaver's investigation will seek to determine whether shareholders were harmed by fraud and deception as Citron claims.
If you have information that could assist in this investigation, or if you are a Mallinckrodt shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.